Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology.
| Revenue (Most Recent Fiscal Year) | $9.62B |
| Net Income (Most Recent Fiscal Year) | $-46.00M |
| PE Ratio (Current Year Earnings Estimate) | 1.52 |
| PE Ratio (Trailing 12 Months) | 1.59 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.23 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 0.77 |
| Pre-Tax Margin (Trailing 12 Months) | 1.94% |
| Net Margin (Trailing 12 Months) | -0.41% |
| Return on Equity (Trailing 12 Months) | -540.45% |
| Return on Assets (Trailing 12 Months) | 5.26% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.35 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.97 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 1.76 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.89 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.59 |
| Earnings per Share (Most Recent Fiscal Year) | $3.96 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.11 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 370.08M |
| Free Float | 340.03M |
| Market Capitalization | $2.21B |
| Average Volume (Last 20 Days) | 1.97M |
| Beta (Past 60 Months) | 0.28 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.12% |
| Percentage Held By Institutions (Latest 13F Reports) | 78.65% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |